Compare · BSX vs KMTS
BSX vs KMTS
Side-by-side comparison of Boston Scientific Corporation (BSX) and Kestra Medical Technologies Ltd. (KMTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and KMTS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $63.97B, about 37.4x KMTS ($1.71B).
- KMTS has been more active in the news (6 items in the past 4 weeks vs 5 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 9 for KMTS).
- Company
- Boston Scientific Corporation
- Kestra Medical Technologies Ltd.
- Price
- -
- -
- Market cap
- $63.97B
- $1.71B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 5
- 6
- Recent ratings
- 25
- 9
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BSX
- Barclays initiated coverage on Boston Scientific with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
- Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
- Boston Scientific Corporation filed SEC Form 8-K: Leadership Update
- Boston Scientific downgraded by Citigroup with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- SEC Form 4 filed by Boston Scientific Corporation
- Director Morano Susan E bought $100,408 worth of shares (2,040 units at $49.22), increasing direct ownership by 17% to 13,784 units (SEC Form 4)
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
Latest KMTS
- Director Cohen Raymond W sold $97,504 worth of shares (3,330 units at $29.28), decreasing direct ownership by 6% to 54,790 units (SEC Form 4) (tax liability)
- Kestra Medical Technologies Earns Five-Star Rating on Newsweek’s List of America’s Greatest Mid-Market Companies
- SEC Form 144 filed by Kestra Medical Technologies Ltd.
- CAIRDAC Announces the Appointment of Raymond W. Cohen as Chairman of its Board of Directors
- Director Kwo Elizabeth sold $97,268 worth of shares (4,010 units at $24.26), decreasing direct ownership by 22% to 14,116 units (SEC Form 4) (withholding obligation)
- SEC Form 144 filed by Kestra Medical Technologies Ltd.
- SEC Form 10-Q filed by Kestra Medical Technologies Ltd.
- Kestra Medical Technologies Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results
- Director Schwartz Jeffrey Lawrence sold $97,942 worth of shares (3,890 units at $25.18) and was granted 7,217 shares, increasing direct ownership by 30% to 14,236 units (SEC Form 4) to satisfy tax liability